This study is looking at whether a drug called **alirocumab** can help reduce inflammation in people with **sepsis**, a serious condition where the body reacts badly to an infection causing organ problems. **Alirocumab** is known to lower cholesterol and might help in sepsis cases. Participants will be randomly chosen to receive either alirocumab or a **placebo** (a harmless fake treatment) through an **IV** (a tube that puts medicine directly into the vein) once for about 30 minutes. The study will follow participants for 180 days to see the effects.

Sepsis can cause life-threatening issues, often leading to long hospital stays. The study aims to find new ways to treat sepsis since existing options are limited. Participants must have a suspected or confirmed infection and certain heart or lung problems to join. They should not have had organ issues for more than 24 hours, certain chronic illnesses, or be pregnant.

• The study lasts for 180 days with a one-time IV treatment.
• Participants will be monitored for how they respond to the treatment.
• Eligibility depends on specific health conditions related to sepsis.